Women with a type of early breast cancer may not benefit from continuing or starting a drug after having surgery, NICE says in draft guidance. NICE already recommends pertuzumab (also called Perjeta and made by Roche), given with trastuzumab and chemotherapy, for treating early HER2-positive breast cancer before surgery. NICE also recommends it for treating HER2-positive breast cancer that has either recurred in the breast following initial treatment or has spread from the breast to elsewhere in the body.
NICE has now published draft guidance which does not recommend pertuzumab for women with HER2 positive early breast cancer who have a high risk of the disease recurring.
A breast cancer charity is accusing CCGs of restricting access to breast reconstruction services for non-clinical reasons. The Breast Cancer Now report, based on a freedom of information request which received responses from around a quarter of CCGs, describes the CCG policies as “totally unacceptable” and ”not in the best interest of patients”. They include limiting the number of surgeries women are allowed, imposing a timeframe on their completion and denying “balancing surgery” to the unaffected breast to achieve symmetry with the reconstruction.
The prime minister, Theresa May, has set out plans for a five-year funding settlement for the NHS, which will receive an increase of £20.5bn a year by the end of the period – an average 3.4% per year overall.
The increase is intended to help the NHS recover lost ground and set the foundations for service improvements. It will be front-loaded with increases of 3.6% in the first two years, which means £4.1 billion extra next year.
PCC offers a number of opportunities for primary care providers to access our services. We have a general medical provider subscription package and also offer subscriptions to groups of practices working together.